Textbook of Cell Signalling in Cancer

Jacques Robert is a Professor of Biological Oncology at the University of Bordeaux, France and currently teaches cell biology, basic oncology and molecular pharmacology to medical and scientific students, with special courses on new developments in cancer targeted therapies. He is an oncobiologist at the department of Biopathology of Institut Bergonié, the Comprehensive cancer centre of Bordeaux, and is responsible for the routine and specialised clinical chemistry tests performed in patients. His research activities at INSERM U916 are focused on the molecular determinants of the activity of anticancer drugs, both at the levels of the patient’s genome (pharmacogenetics) and at the level of the tumour genome (pharmacogenomics). This activity is developed on both in vitro and in vivo models and at the level of clinical studies aiming at identifying the genetic factors involved in the efficiency and toxicity of classical and targeted anticancer drugs, especially in colorectal, head-and-neck and breast cancers.

Growth Factors and Tyrosine Kinase Receptors.- MAP Kinases Pathway.- Phosphatidylinositol 3-Kinase Pathway.- Cytokine Pathway.- TGFbeta Pathway.- G-proteins-coupled Receptors.- Wnt Pathway.- Notch Pathway.- Hedgehog Pathway.- Integrins.- Semaphorins and Adhesion Molecules.- Toll-like Receptors, Interleukin 1 (IL1) and NF B.- Lymphocyte Receptors Pathways.- Nuclear Receptors Pathways.- Ion Channels-coupled Receptors.- Signalling by Oxygen and Nitric Oxide.- Cell Cycle Control.- Apoptosis Induction and Regulation.

lt;p>"Aiming not only at helping the medical oncology community, especially those who are in daily practice, but also the pharmacologists, physicians and scientists in the pharmaceutical industry, this textbook provides a very useful guide. ... Each chapter is followed by selected and updated bibliographic references. This textbook is a very valuable didactic aid to the clinical oncologist and to those in the pharmaceutical industry who are interested in anticancer agents." (Ferdy J. Lejeune, Melanoma Research, Vol. 26, 2016)